Blogger Archives: John Connolly

John Connolly

John Connolly is Willis Towers Watson’s North American Practice Leader for life science and pharmaceuticals. Based in Philadelphia, he leads a network of more than 150 colleagues. John joined Willis in August, 2007 and has worked in the insurance industry for 30 years—more than 15 of them focused on the life sciences industry. John has twice been designated one of Risk and Insurance Managers’ “Power Brokers.”

Who benefits from the 21st Cures Act?

On December 13, 2016, President Obama signed into law the 21st Century Cures Act (“Cures Act”). The legislation was designed to accelerate regulatory pathways for regenerative therapies to meet severe unmet medical needs. Within its provisions, the Bill will support President Obama and … Continue reading →

Now That 3D Printing is Creating Medical Devices, What Regulatory and Liability Challenges Loom?

In 3D printing, a computer creates software containing a product design then sends it to printers, which manufacture the final product from a variety of materials including plastics, metals, drugs and, now, human tissue. 3D printing offers the promise of … Continue reading →

Potential Economic and Safety Impacts of the FDA’s New Generic Drug-Labeling Rule

The FDA has proposed changes in the regulations that govern the rights and duties of generic drug manufacturers to update safety information in product labeling. Over the course of the next 12 months it is likely that the FDA will … Continue reading →

Posts by Author in Portuguese:

Impressoras 3D e dispositivos médicos: quais são os desafios regulatórios e de responsabilidade?

Na impressão 3D, um computador cria um software contendo um projeto de produto, em seguida, envia para as impressoras, que fabricam o produto final de uma variedade de materiais, incluindo plásticos, metais, drogas e, agora, até o tecido humano. Continuar lendo →